Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
复制标题
DOI：
10.1002/jso.21954
复制
发表时间：
2011-08-01
影响因子：
2.5
通讯作者：
Springett, Gregory
中科院分区：
文献类型：
--
作者：
Patel, Manish;Hoffe, Sarah;Malafa, Mokenge;Hodul, Pamela;Klapman, Jason;Centeno, Barbara;Kim, Jongphil;Helm, James;Valone, Tiffany;Springett, Gregory
为了提高实现无边缘切除的可能性，对边缘可切除的胰腺癌患者给予GTX（吉西他滨，多西他赛和卡培他滨）的新辅助诱导化疗，随后给予5-FU-IMRT。CT， EUS， PET和CA 19-9在诊断检查和反应评估中的应用也被检查。17例边缘性可切除胰腺癌患者接受了中位数为3个周期的新辅助GTX诱导化疗，随后进行5-FU-IMRT剂量涂绘。新辅助治疗前后检测CA 19-9、CT肿块大小、PET SUV。诊断性EUS和CT扫描显示相似的平均肿块大小和血管受累范围。17例患者中有8例完成了R0切除术。新辅助治疗后，中位CA 19-9水平、CT肿块大小和PET SUV均显著降低。中位无进展生存期和总生存期分别为10.48个月和15.64个月。6名患者仍然活着。新辅助GTX诱导化疗后5-FU-IMRT有望提高边缘可切除胰腺癌阴性切缘的可切除性。CT和EUS在诊断检查中起互补作用。CT扫描、CA 19-9和PET扫描可用于判断新辅助治疗的反应。
To improve the likelihood of achieving a margin-free resection, neoadjuvant induction chemotherapy with GTX (gemcitabine, docetaxel, and capecitabine) followed by 5-FU-IMRT was administered to patients with borderline resectable pancreatic cancer. The utility of CT, EUS, PET, and CA 19-9 during diagnostic workup and assessment of response was also examined. Seventeen patients with borderline resectable pancreatic cancer received a median of 3 cycles of neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT with dose painting. CA 19-9, CT mass size, and PET SUV were examined before and after neoadjuvant treatment. Diagnostic EUS and CT scans displayed similar mean mass sizes and extent of vascular involvement. Eight of the 17 patients achieved an R0 resection. Median CA 19-9 levels, CT mass size, and PET SUV all significantly decreased after neoadjuvant therapy. The median progression-free survival and overall survival were 10.48 months and 15.64 months respectively. Six patients are still alive. Neoadjuvant GTX induction chemotherapy followed by 5-FU-IMRT shows promise in improving the likelihood of resectability with negative margins in borderline resectable pancreatic cancer. CT and EUS play complimentary roles during diagnostic workup. CT scans, CA 19-9, and PET scans are useful in judging response to neoadjuvant therapy.
登录
查看更多内容
影响因子：
45.3
作者：
Crane, CH;Ellis, LM;Wolff, R
通讯作者：
Wolff, R
DOI：
10.1016/s0360-3016(01)02740-7
发表时间：
2002-04-01
影响因子：
7
作者：
Crane, CH;Abbruzzese, JL;Janjan, NA
通讯作者：
Janjan, NA
影响因子：
9
作者：
Neoptolemos, JP;Stocken, DD;Büchler, MW
通讯作者：
Büchler, MW
DOI：
10.1016/s0360-3016(02)02902-4
发表时间：
2002-09-01
影响因子：
7
作者：
Safran, H;Dipetrillo, T;Rich, T
通讯作者：
Rich, T
影响因子：
3.7
作者：
KAPLAN, EL;MEIER, P
通讯作者：
MEIER, P